Atyr_Logo.png
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
May 14, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Atyr_Logo.png
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
May 02, 2024 16:00 ET | aTyr Pharma, Inc.
aTyr Pharma announces first quarter 2024 results and provides corporate update
Molecure_logo-removebg-preview.png
First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
March 22, 2024 04:00 ET | Molecure
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the...
Atyr_Logo.png
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
March 14, 2024 16:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
Atyr_Logo.png
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
February 21, 2024 08:00 ET | aTyr Pharma, Inc.
Tyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
Atyr_Logo.png
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
January 29, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma to present posters on the importance of Neuropilin-2 in immune regulation at the Keystone Symposia on Myeloid Cell Diversity.
Atyr_Logo.png
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
January 18, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).
Molecure_logo-removebg-preview.png
Molecure Announces Third Quarter 2023 Financial Results and Pipeline Highlights
October 31, 2023 04:00 ET | Molecure
U.S. Food and Drug Administration (FDA) approval to conduct a Phase II clinical trial for novel chitinase inhibitor OATD-01 in pulmonary sarcoidosis with first patient expected to be dosed in fourth...
Orphai071d FINAL low res.jpg
AI Therapeutics Announces Name Change to OrphAI Therapeutics
September 28, 2023 11:38 ET | AI Therapeutics, Inc.
GUILFORD, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today that it has...
Atyr_Logo.png
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
September 11, 2023 08:00 ET | aTyr Pharma, Inc.
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...